ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,626.02
      0.54%
      US Tech 100
      18,986.40
      0.30%
      Dow Jones
      41,393.78
      0.72%
      Brent Oil
      71.825
      0.00%
      Bitcoin
      60,049.38
      0.07%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AN2 Therapeutics Inc (ANTX) Quote

      AN2 Therapeutics Inc

      AN2 Therapeutics Inc (ANTX)

      NASDAQ
      1.04
      0.00
      (0.00%)
      Closed September 14 4:00PM
      Delayed by 15 minutes
      1.04
      0.00
      (0.00%)
      After Hours: 4:22PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.04
      Bid
      1.01
      Ask
      1.05
      Volume
      219,275
      1.02 Day's Range 1.06
      0.87 52 Week Range 23.58
      Market Cap
      31.036M
      Previous Close
      1.04
      Open
      1.03
      Last Trade
      3558
      @
      1.04
      Last Trade Time
      Financial Volume
      $ 227,382
      VWAP
      1.037
      Average Volume (3m)
      425,669
      Shares Outstanding
      29,842,431
      Dividend Yield
      -
      PE Ratio
      -0.48
      Earnings Per Share (EPS)
      -2.17
      Revenue
      -
      Net Profit
      -64.73M

      About AN2 Therapeutics Inc

      AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.an2therapeutics.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was $1.04. Over the last year, AN2 Therapeutics shares have traded in a share price range of $ 0.87 to $ 23.58.

      AN2 Therapeutics currently has 29,842,431 shares outstanding. The market capitalization of AN2 Therapeutics is $31.04 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

      Ask ADVFN Intelligence (AI)

      ANTX Latest News

      More News

      AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

      AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

      August 28 2024
      Business Wire

      Form 8-A12B - Registration of securities [Section 12(b)]

      August 19 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 19 2024
      Edgar (US Regulatory)

      AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

      AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

      August 16 2024
      Business Wire

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 13 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 13 2024
      Edgar (US Regulatory)

      AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

      Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical...

      August 13 2024
      Business Wire

      Form 8-K - Current report

      August 08 2024
      Edgar (US Regulatory)

      AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

      EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...

      August 08 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      July 12 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1001.041.190.956533451.07197583CS
      4-1.02-49.51456310682.063.070.876415731.25881664CS
      12-1.85-64.01384083042.893.880.874256691.74884483CS
      26-14.82-93.442622950815.8622.220.873221334.02293737CS
      52-15.81-93.827893175116.8523.580.871658165.56677675CS
      156-15.81-93.827893175116.8523.580.871658165.56677675CS
      2600001.08000CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NOVVUNova Vision Acquisition Corporation
      $ 41.00
      (207.35%)
      		17.4k
      NOVVNova Vision Acquisition Corporation
      $ 37.0001
      (200.08%)
      		205.22k
      SMXSMX Security Matters Public Company
      $ 5.85
      (138.78%)
      		50.1M
      OMICSingular Genomics Systems Inc
      $ 12.38
      (119.12%)
      		2.87M
      TILInstill Bio Inc
      $ 84.75
      (82.41%)
      		3.91M
      GSIWGarden Stage Ltd
      $ 2.9693
      (-75.66%)
      		4.24M
      UPCUniverse Pharmaceuticals Inc
      $ 0.55
      (-67.07%)
      		30.45M
      VMARVision Marine Technologies Inc
      $ 0.77
      (-48.67%)
      		34.54M
      PRLDPrelude Therapeutics Inc
      $ 2.775
      (-42.55%)
      		2.49M
      CNEYCN Energy Group Inc
      $ 0.4335
      (-37.17%)
      		5.06M
      NVDANVIDIA Corporation
      $ 119.10
      (-0.03%)
      		225.83M
      XXII22nd Century Group Inc
      $ 0.3447
      (28.00%)
      		168.56M
      IMRXImmuneering Corporation
      $ 2.02
      (41.26%)
      		131.85M
      SQQQProShares UltraPro Short QQQ
      $ 8.17
      (-1.33%)
      		122.46M
      MULNMullen Automotive Inc
      $ 0.1328
      (-20.48%)
      		119.52M

      ANTX Discussion

      View Posts
      Monksdream Monksdream 1 month ago
      ANTX new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      ANTX under $3
      👍️0
      eyeownu eyeownu 2 months ago
      looking good
      👍️0
      glenn1919 glenn1919 2 months ago
      ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 5 months ago
      FROM 3/28 NEWS:

      Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

      GO4AWILDRIDE
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 5 months ago
      THE FOLLOWING FROM THE 3/28 NEWS:

      “AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

      GO4AWILDRIDE
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 5 months ago
      Monksdream

      Did you read the 3/28 news from the compay?

      Seems like the market is looking to chase the price up.

      GLTU

      GO4AWILDRIDE
      👍️0
      GO4AWILDRIDE GO4AWILDRIDE 5 months ago
      Monksdream

      Seems like a nice rebound is starting to occur.

      GLTU

      GO4AWILDRIDE
      👍️0
      Monksdream Monksdream 6 months ago
      ANTX new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      ANTX new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      ANTX new 52 week low
      👍️0

      Your Recent History

      NASDAQ
      ANTX
      AN2 Therapeutics
      Delayed Upgrade Clock